AI assistant
NEOGENOMICS INC — Director's Dealing 2025
Apr 3, 2025
32227_dirs_2025-04-03_72af2050-83a5-4bc5-853d-38e817b731e2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2025-04-01
Reporting Person: Zook Anthony P. (Director, Chief Executive Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-04-01 | Stock Option (Right to Buy) | $10.44 | A | 729927 | Acquired | 2035-04-01 | Common Stock (729927) | Direct |
| 2025-04-01 | Restricted Stock Unit | $0 | A | 421496 | Acquired | Common Stock (421496) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 11336 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $14.82 | 2033-08-10 | Common Stock (8353) | 8353 | Direct |
| Stock Option (Right to Buy) | $13.71 | 2034-06-01 | Common Stock (8672) | 8672 | Direct |
| Restricted Stock Unit | $0 | Common Stock (12254) | 12254 | Direct |
Footnotes
F1: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%.
F2: On April 1, 2025, Mr. Zook was granted 729,927 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F3: On April 1, 2025, Mr. Zook was granted 421,496 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F4: Once vested, the shares of common stock are not subject to expiration.